ClinicalTrials.govpublic full text
Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS
ards, human, covid, covid-19, ards, ruxolitinib, janus kinase, jak1, jak2, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 904323
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.